SCHEMBL31349532

SCHEMBL31349532

O=C1CC(n2cnc3cc(OCCBr)cc(C(F)(F)F)c32)CN1

nearest known ligand 0.41

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ ABL1 P00519 3/20 0.41
▸ SLC5A1 P13866 6/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31349586 0.85 HTR2A (0.30) —
SCHEMBL31349568 0.82 ABL1 (0.41) ABL1
SCHEMBL31436566 0.81 — —
SCHEMBL31349529 0.80 PIK3CD (0.32) ABL1
SCHEMBL31349528 0.80 ABL1 (0.42) ABL1SLC5A1
SCHEMBL25317096 0.78 AR (0.35) ABL1
SCHEMBL26024404 0.78 AR (0.35) ABL1
SCHEMBL30506754 0.78 AR (0.35) ABL1
SCHEMBL31349483 0.77 EPHX2 (0.38) —
SCHEMBL31349655 0.74 ABL1 (0.34) ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4743078-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2026-05-20 — — EP disclosed
WO-2025015104-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2025-01-16 — — WO disclosed
Send feedback